Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
March 25, 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, March 25, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of two new...
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress
March 24, 2021 16:01 ET
|
Abeona Therapeutics Inc.
Fourth patient treated in pivotal Phase 3 VIITAL™ study of EB-101 in RDEB after successful Type B meeting with FDA Positive new interim data from MPS IIIA and MPS IIIB programs presented at 17th...
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer
March 22, 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, March 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso,...
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 22, 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company will present...
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy
February 12, 2021 11:36 ET
|
Abeona Therapeutics Inc.
In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained...
Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™
February 02, 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it will host a live...
Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
January 25, 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company held a...
Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™
December 21, 2020 12:20 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that abstracts detailing new...
Abeona Therapeutics Reports Third Quarter Financial Results
November 09, 2020 16:05 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced financial results for the third...
Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer
October 27, 2020 06:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Senior...